CELLBXHEALTH PLC Stock Price, News & Analysis

ANGLE plc has announced significant findings from a study on triple negative breast cancer (TNBC) using their Parsortix system. Conducted by the Fondazione IRCCS Istituto Nazionale dei Tumori, the research shows that Parsortix can harvest intact circulating tumor cells (CTCs) for whole genome sequencing, identifying actionable genetic targets. The study revealed treatment-induced resistance and highlights the utility of CTC analysis for personalized medicine in patients with limited treatment options. The findings have been published in Scientific Reports.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has received a Certificate of Registration from the Centers for Medicare and Medicaid Services (CMS) for its US clinical laboratory, marking a significant step towards achieving CLIA accreditation.

This accreditation will enable the laboratory to process samples for patient management across most US states. Following a CMS audit, a Certificate of Compliance will be issued. With laboratory accreditation progressing in both the US and UK, ANGLE aims to enhance its commercial offerings and support its pharma services business, as noted by Chief Medical Officer, Dr. Todd Druley.

ANGLE plc announced that as of February 25, 2022, Morgan Stanley Investment Management Inc. has reduced its voting rights in the company to 4.82%, down from a previous holding above 5%. The notification reflects a significant change in the investment management strategy of Morgan Stanley, which now manages 11,328,548 voting rights in ANGLE plc. This marks a notable shift since they previously surpassed the threshold in January 2021 with a holding of 5.32%.

ANGLE plc has issued 6,667 new ordinary shares following the exercise of employee options, increasing the total shares to 235,149,717. These shares will be admitted to trading on AIM, effective 8:00 a.m. on February 24, 2022. The company is recognized for its innovative liquid biopsy technology, including the Parsortix system, which enables effective analysis of circulating tumor cells (CTCs). ANGLE aims to be the first to receive FDA clearance for CTC harvesting, enhancing its competitive position in the oncology market.

ANGLE plc announces a peer-reviewed study from Edith Cowan University demonstrating the effectiveness of the Parsortix system in isolating circulating tumor cells (CTCs) in ovarian cancer patients. The study shows a significant correlation between PD-L1 expression and CTCs undergoing epithelial to mesenchymal transition (EMT). Among 16 patients, 63% had detectable CTCs, with 50% being PD-L1 positive. The results suggest that using the Parsortix system could enhance patient selection for immunotherapy, addressing the need for improved treatment outcomes where current response rates are low.

ANGLE plc announced a groundbreaking study establishing the concordance of its Parsortix liquid biopsy blood test with invasive tissue biopsy in metastatic breast cancer (MBC) patients. Conducted by experts at the University of Southern California, the study indicates that over 50% of MBC patients are unable to undergo successful tissue biopsies due to various factors. With a pilot study involving 19 patients, the Parsortix test demonstrated high concordance in RNA sequencing results, potentially offering a non-invasive alternative to guide treatment decisions effectively. This research contributes significant insights into cancer monitoring and personalized therapy.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has updated on its laboratory accreditation and ovarian cancer study. The company has submitted its accreditation requests for its clinical laboratories in the US and UK. However, supply chain issues have delayed the analysis of ovarian cancer study samples, now expected to finalize in H1 2022. Despite these challenges, ANGLE remains optimistic about obtaining FDA clearance for its Parsortix system, designed to harvest cancer cells from blood, while continuing discussions with the FDA regarding its regulatory decision.

ANGLE plc announced significant findings from a study on non-small cell lung cancer (NSCLC) patients with EGFR mutations treated with Osimertinib. The research, led by Prof. Evi Lianidou, highlights the importance of analyzing both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) for understanding drug resistance mechanisms. The study revealed elevated DNA methylation in cancer-related genes at disease progression, suggesting a link between these alterations and Osimertinib resistance. Liquid biopsies offer safer, cost-effective longitudinal monitoring of cancer evolution, supporting precision medicine initiatives.

ANGLE plc (OTCQX:ANPCY) has announced the issuance of 6,666 new ordinary shares following the exercise of employee options. These shares will rank equally with existing shares, expanding the total to 235,143,050 shares. An application for admission to trading on AIM has been made, expected to take effect on December 30, 2021. The company is recognized for its innovative liquid biopsy technology, particularly the Parsortix system, which captures circulating tumor cells for various analyses, showcasing a commitment to advancing cancer diagnostics and treatment.